Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.
After allogeneic stem cell transplantation (alloSCT), several immune checkpoints play an important role in the antileukemic immune response in the bone marrow (BM) microenvironment. However, immune checkpoint expression levels in the BM have not been reported after alloSCT in patients with acute myeloid leukemia (AML). We investigated the clinical impact of immune checkpoint expression in BM samples after alloSCT for AML. Higher expression of T cell immunoreceptor with Ig and ITIM domains (TIGIT) was associated with a decreased incidence of acute graft-versus-host disease (P = .048) and poor overall (P = .046) and progression-free survival (P = 0.024). In addition, higher expression of TIGIT at engraftment after alloSCT was correlated with a decreased number of natural killer cells in BM (P = .019). Monitoring TIGIT expression in the BM could be useful for predicting outcome after alloSCT for AML. Our findings raise the possibility that blockade of TIGIT would improve survival.
['Hattori|Norimichi|N|', 'Kawaguchi|Yukiko|Y|', 'Sasaki|Yohei|Y|', 'Shimada|Shotaro|S|', 'Murai|So|S|', 'Abe|Maasa|M|', 'Baba|Yuta|Y|', 'Watanuki|Megumi|M|', 'Fujiwara|Shun|S|', 'Arai|Nana|N|', 'Kabasawa|Nobuyuki|N|', 'Tsukamoto|Hiroyuki|H|', 'Uto|Yui|Y|', 'Yanagisawa|Kouji|K|', 'Saito|Bungo|B|', 'Harada|Hiroshi|H|', 'Nakamaki|Tsuyoshi|T|']
D000945:Antigens, Differentiation, T-Lymphocyte D001853:Bone Marrow D006086:Graft vs Host Disease D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D007109:Immunity D007694:Killer Cells, Natural D015470:Leukemia, Myeloid, Acute D015166:Monitoring, Immunologic D011971:Receptors, Immunologic D011991:Receptors, Virus D013534:Survival D014184:Transplantation, Homologous
TIGIT DNAM-1 PVR Immune checkpoints Allogeneic stem cell transplantation PVRL1